Current therapy of the pemphigus group

Michael Kasperkiewicz; Enno Schmidt; Detlef Zillikens

doi:10.1016/j.clindermatol.2011.03.014

Current therapy of the pemphigus group

Michael Kasperkiewicz^*, Enno Schmidt, Detlef Zillikens

^*Corresponding author for this work

Department of Dermatology, Allergology and Venereology

70 Citations (Scopus)

Abstract

Treatment of pemphigus patients is still challenging and, in some cases, conventional therapy with systemic corticosteroids in combination with adjuvant corticosteroid-sparing immunosuppressive drugs is not sufficient to induce clinical remission. More recently, high-dose intravenous immunoglobulins, immunoadsorption, and the monoclonal anti-CD20 antibody, rituximab, have been established as additional successful therapeutic options. This contribution covers both conventional therapies and most current treatment strategies for pemphigus.

Original language	English
Journal	Clinics in Dermatology
Volume	30
Issue number	1
Pages (from-to)	84-94
Number of pages	11
ISSN	0738-081X
DOIs	https://doi.org/10.1016/j.clindermatol.2011.03.014
Publication status	Published - 01.01.2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.clindermatol.2011.03.014

Cite this

@article{8f0565ab96014f49aa5d68c68c1ef893,

title = "Current therapy of the pemphigus group",

abstract = "Treatment of pemphigus patients is still challenging and, in some cases, conventional therapy with systemic corticosteroids in combination with adjuvant corticosteroid-sparing immunosuppressive drugs is not sufficient to induce clinical remission. More recently, high-dose intravenous immunoglobulins, immunoadsorption, and the monoclonal anti-CD20 antibody, rituximab, have been established as additional successful therapeutic options. This contribution covers both conventional therapies and most current treatment strategies for pemphigus.",

author = "Michael Kasperkiewicz and Enno Schmidt and Detlef Zillikens",

year = "2012",

month = jan,

day = "1",

doi = "10.1016/j.clindermatol.2011.03.014",

language = "English",

volume = "30",

pages = "84--94",

journal = "Clinics in Dermatology",

issn = "0738-081X",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Current therapy of the pemphigus group

AU - Kasperkiewicz, Michael

AU - Schmidt, Enno

AU - Zillikens, Detlef

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Treatment of pemphigus patients is still challenging and, in some cases, conventional therapy with systemic corticosteroids in combination with adjuvant corticosteroid-sparing immunosuppressive drugs is not sufficient to induce clinical remission. More recently, high-dose intravenous immunoglobulins, immunoadsorption, and the monoclonal anti-CD20 antibody, rituximab, have been established as additional successful therapeutic options. This contribution covers both conventional therapies and most current treatment strategies for pemphigus.

AB - Treatment of pemphigus patients is still challenging and, in some cases, conventional therapy with systemic corticosteroids in combination with adjuvant corticosteroid-sparing immunosuppressive drugs is not sufficient to induce clinical remission. More recently, high-dose intravenous immunoglobulins, immunoadsorption, and the monoclonal anti-CD20 antibody, rituximab, have been established as additional successful therapeutic options. This contribution covers both conventional therapies and most current treatment strategies for pemphigus.

UR - https://www.scopus.com/pages/publications/83155160947

U2 - 10.1016/j.clindermatol.2011.03.014

DO - 10.1016/j.clindermatol.2011.03.014

M3 - Journal articles

C2 - 22137231

AN - SCOPUS:83155160947

SN - 0738-081X

VL - 30

SP - 84

EP - 94

JO - Clinics in Dermatology

JF - Clinics in Dermatology

IS - 1

ER -

Current therapy of the pemphigus group

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this